Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development

Toxicological Sciences

Volumn 118, Issue 2, 2010, Pages 485-500

  Morgan, Ryan E ^a   Trauner, Michael ^b   van Staden, Carlo J ^c   Lee, Paul H ^c   Ramachandran, Bharath ^a   Eschenberg, Michael ^a   Afshari, Cynthia A ^a   Qualls, Charles W ^a   Lightfoot Dunn, Ruth ^a   Hamadeh, Hisham K ^a  

^a AMGEN INC   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Lead Discovery ^*  (United States)

Author keywords

Bile salt export pump; Bile salt transport; BSEP; Hepatobiliary transport; Hepatotoxicity; Liver

Indexed keywords

BILE SALT; BILE SALT EXPORT PUMP; BOSENTAN; CARRIER PROTEIN; CLOFAZIMINE; ERYTHROMYCIN ESTOLATE; FENOFIBRATE; FUSIDIC ACID; GEFITINIB; GLIBENCLAMIDE; INDOMETACIN; KETOCONAZOLE; LAPATINIB; NEFAZODONE; NELFINAVIR; NICARDIPINE; NORETHISTERONE; PAZOPANIB; PIOGLITAZONE; RESERPINE; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; SORAFENIB; TELITHROMYCIN; TOLCAPONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINOMYCIN; WORTMANNIN;

ANIMAL CELL; ARTICLE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG POTENCY; GENETIC TRANSFECTION; INSECT CELL; LIVER INJURY; LIVER TOXICITY; MEMBRANE VESICLE; NONHUMAN; PHYSICAL CHEMISTRY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL ASSAY; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE; CYTOPLASMIC VESICLES; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; RATS; REPRODUCIBILITY OF RESULTS; SPODOPTERA; TRANSFECTION; XENOBIOTICS;

ANIMALIA; HEXAPODA;

EID: 78549248177     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq269     Document Type: Article

References (77)

1. Akashi, M., Tanaka, A., and Takikawa, H. (2006). Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats. Hepatol. Res. 34, 193-198.
2. Alissa, F.T., Jaffe, R., and Shneider, B.L. (2008). Update on progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 46, 241-252.
3. Alrefai, W.A., and Gill, R.K. (2007). Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24, 1803-1823.
4. Benedetti, M.S. (1995). Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol. Res. 32, 177-187.
5. Boelsterli, U.A., Ho, H.K., Zhou, S., and Leow, K.Y. (2006). Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr. Drug Metab. 7, 715-727.
6. Boelsterli, U.A., and Lim, P.L. (2007). Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220, 92-107.
7. Borst, P., de Wolf, C., and van de Wetering, K. (2007). Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453, 661-673.
8. Byrne, J.A., Strautnieks, S.S., Ihrke, G., Pagani, F., Knisely, A.S., Linton, K.J., Mieli-Vergani, G., and Thompson, R.J. (2002). The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123, 1649-1658.
9. Byrne, J.A., Strautnieks, S.S., Mieli-Vergani, G., Higgins, C.F., Linton, K.J., and Thompson, R.J. (2009). Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing. Hepatology 49, 553-567.
10. Chiang, J.Y. (2009). Bile acids: regulation of synthesis. J. Lipid Res. 50, 1955-1966.
11. Davit-Spraul, A., Gonzales, E., Baussan, C., and Jacquemin, E. (2009). Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 4, 1.
12. Dawson, P.A., Lan, T., and Rao, A. (2009). Bile acid transporters. J. Lipid Res. 50, 2340-2357.
13. Dixon, P.H., van Mil, S.W., Chambers, J., Strautnieks, S., Thompson, R.J., Lammert, F., Kubitz, R., Keitel, V., Glantz, A., Mattsson, L.A., Marschall, H.U., et al. (2009). Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 58, 537-544.
14. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., and Meier, P.J. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231.
15. Feng, B., Xu, J.J., Bi, Y.A., Mireles, R., Davidson, R., Duignan, D.B., Campbell, S., Kostrubsky, V.E., Dunn, M.C., Smith, A.R., et al. (2009). Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci. 108, 492-500.
16. Fomenko, I., Durst, M., and Balaban, D. (2006). Robust regression for high throughput drug screening. Comput. Methods Programs Biomed. 82, 31-37.
17. Fouassier, L., Kinnman, N., Lefevre, G., Lasnier, E., Rey, C., Poupon, R., Elferink, R.P., and Housset, C. (2002). Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37, 184-191.
18. Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. (2001). Cholestatic potential of troglitazone as a possible factor contributing to troglitazoneinduced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627-635.
19. Geier, A., Wagner, M., Dietrich, C.G., and Trauner, M. (2007). Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773, 283-308.
20. Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A.F., and Meier, P.J. (1998). The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273, 10046-10050.
21. Giri, S., Nieber, K., and Bader, A. (2010). Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages. Expert Opin. Drug Metab. Toxicol. 6, 895-917.
22. Griffith, D.E., Brown, B.A., Girard, W.M., and Wallace, R.J., Jr. (1995). Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 21, 594-598.
23. Hamadeh, H.K., Todd, M., Healy, L., Meyer, J.T., Kwok, A.M., Higgins, M., and Afshari, C.A. (2010). Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors. Chem. Res. Toxicol. 23, 1025-1033.
24. Hinson, J.A., Roberts, D.W., and James, L.P. (2010). Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. 196, 369-405.
25. Hirano, M., Maeda, K., Hayashi, H., Kusuhara, H., and Sugiyama, Y. (2005). Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314, 876-882.
26. Hofmann, A.F. (1999). The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159, 2647-2658.
27. Horikawa, M., Kato, Y., Tyson, C.A., and Sugiyama, Y. (2003). Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab. Pharmacokinet 18, 16-22.
28. Iwanaga, T., Nakakariya, M., Yabuuchi, H., Maeda, T., and Tamai, I. (2007). Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biol. Pharm. Bull. 30, 739-744.
29. Jara, P., Hierro, L., Martinez-Fernandez, P., Alvarez-Doforno, R., Yanez, F., Diaz, M.C., Camarena, C., De la Vega, A., Frauca, E., Munoz-Bartolo, G., et al. (2009). Recurrence of bile salt export pump deficiency after liver transplantation. N. Engl. J. Med. 361, 1359-1367.
30. Julie, N.L., Julie, I.M., Kende, A.I., and Wilson, G.L. (2008). Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone. Diabetologia 51, 2108-2116.
31. Kagawa, T., Watanabe, N., Mochizuki, K., Numari, A., Ikeno, Y., Itoh, J., Tanaka, H., Arias, I.M., and Mine, T. (2008). Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G58-G67.
32. Keitel, V., Burdelski, M., Vojnisek, Z., Schmitt, L., Haussinger, D., and Kubitz, R. (2009). De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology 50, 510-517.
33. Kemp, D.C., Zamek-Gliszczynski, M.J., and Brouwer, K.L. (2005). Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol. Sci. 83, 207-214.
34. Klaassen, C.D., and Aleksunes, L.M. (2010). Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 62, 1-96.
35. Kostrubsky, S.E., Strom, S.C., Ellis, E., Nelson, S.D., and Mutlib, A.E. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451-459.
36. Kostrubsky, S.E., Strom, S.C., Kalgutkar, A.S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., et al. (2007). Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites. Chem. Res. Toxicol. 20, 1503-1512.
37. Kostrubsky, V.E., Strom, S.C., Hanson, J., Urda, E., Rose, K., Burliegh, J., Zocharski, P., Cai, H., Sinclair, J.F., and Sahi, J. (2003). Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. 76, 220-228.
38. Lam, C.W., Cheung, K.M., Tsui, M.S., Yan, M.S., Lee, C.Y., and Tong, S.F. (2006). A patient with novel ABCB11 gene mutations with phenotypic transition between BRIC2 and PFIC2. J. Hepatol. 44, 240-242.
39. Lee, J., Azzaroli, F., Wang, L., Soroka, C.J., Gigliozzi, A., Setchell, K.D., Kramer, W., and Boyer, J.L. (2001). Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 121, 1473-1484.
40. Lee, W.M. (2003). Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485.
41. Leslie, E.M., Watkins, P.B., Kim, R.B., andBrouwer, K.L.(2007). Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321, 1170-1178.
42. Liu, X., Brouwer, K.L., Gan, L.S., Brouwer, K.R., Stieger, B., Meier, P.J., Audus, K.L., and LeCluyse, E.L. (1998). Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharm. Res. 15, 1533-1539.
43. Liu, X., LeCluyse, E.L., Brouwer, K.R., Gan, L.S., Lemasters, J.J., Stieger, B., Meier, P.J., and Brouwer, K.L. (1999a). Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol. 277, G12-G21.
44. Liu, X., LeCluyse, E.L., Brouwer, K.R., Lightfoot, R.M., Lee, J.I., and Brouwer, K.L. (1999b). Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 289, 1592-1599.
45. Lundell, K., and Wikvall, K. (2008). Species-specific and age-dependent bile acid composition: aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr. Drug Metab. 9, 323-331.
46. Maddrey, W.C. (2005). Drug-induced hepatotoxicity: 2005. J. Clin. Gastroenterol. 39, S83-S89.
47. Manibusan, M.K., Odin, M., and Eastmond, D.A. (2007). Postulated carbon tetrachloride mode of action: a review. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 25, 185-209.
48. Marschall, H.U., Wagner, M., Zollner, G., and Trauner, M. (2007). Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol. Pharm 4, 895-910.
49. McRae, M.P., Lowe, C.M., Tian, X., Bourdet, D.L., Ho, R.H., Leake, B.F., Kim, R.B., Brouwer, K.L., and Kashuba, A.D. (2006). Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther. 318, 1068-1075.
50. Mita, S., Suzuki, H., Akita, H., Hayashi, H., Onuki, R., Hofmann, A.F., and Sugiyama, Y. (2005). Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G159-G167.
51. Mita, S., Suzuki, H., Akita, H., Hayashi, H., Onuki, R., Hofmann, A.F., and Sugiyama, Y. (2006a). Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab. Dispos. 34, 1575-1581.
52. Mita, S., Suzuki, H., Akita, H., Stieger, B., Meier, P.J., Hofmann, A.F., and Sugiyama, Y. (2006b). Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G550-G556.
53. Nies, A.T., and Keppler, D. (2007). The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453, 643-659.
54. Palmeira, C.M., and Rolo, A.P. (2004). Mitochondrially-mediated toxicity of bile acids. Toxicology 203, 1-15.
55. Pauli-Magnus, C., and Meier, P.J. (2005). Hepatocellular transporters and cholestasis. J. Clin. Gastroenterol. 39, S103-S110.
56. Pauli-Magnus, C., and Meier, P.J. (2006). Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44, 778-787.
57. Ramachandran, R., and Kakar, S. (2009). Histological patterns in drug-induced liver disease. J. Clin. Pathol. 62, 481-492.
58. Rolo, A.P., Palmeira, C.M., Holy, J.M., and Wallace, K.B. (2003). Mitochondrially mediated synergistic cell killing by bile acids. Biochim. Biophys. Acta 1637, 127-132.
59. Rolo, A.P., Palmeira, C.M., and Wallace, K.B. (2004). Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: the switch between apoptosis and necrosis. Toxicol. Sci. 79, 196-204.
60. Saito, H., Osumi, M., Hirano, H., Shin, W., Nakamura, R., and Ishikawa, T. (2009). Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP). AAPS J. 11, 581-589.
61. Sakurai, A., Kurata, A., Onishi, Y., Hirano, H., and Ishikawa, T. (2007). Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf. 6, 71-86.
62. Setchell, K.D., Rodrigues, C.M., Clerici, C., Solinas, A., Morelli, A., Gartung, C., and Boyer, J. (1997). Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 112, 226-235.
63. Snow, K.L., and Moseley, R.H. (2007). Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci. 80, 732-740.
64. Spahr, L., Rubbia-Brandt, L., Burkhard, P.R., Assal, F., and Hadengue, A. (2000). Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig. Dis. Sci. 45, 1881-1884.
65. Stieger, B. (2009). Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab. Rev 42, 437-445.
66. Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G.A., and Meier, P.J. (2000). Drug-and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118, 422-430.
67. Stieger, B., Meier, Y., and Meier, P.J. (2007). The bile salt export pump. Pflugers Arch. 453, 611-620.
68. Strautnieks, S.S., Bull, L.N., Knisely, A.S., Kocoshis, S.A., Dahl, N., Arnell, H., Sokal, E., Dahan, K., Childs, S., Ling, V., et al. (1998). A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20, 233-238.
69. Strautnieks, S.S., Byrne, J.A., Pawlikowska, L., Cebecauerova, D., Rayner, A., Dutton, L., Meier, Y., Antoniou, A., Stieger, B., Arnell, H., et al. (2008). Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 134, 1203-1214.
70. Trauner, M., and Boyer, J.L. (2003). Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83, 633-671.
71. Vuppalanchi, R., Chalasani, N., and Saxena, R. (2006). Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am. J. Surg. Pathol. 30, 1619-1623.
72. Wang, R., Chen, H.L., Liu, L., Sheps, J.A., Phillips, M.J., and Ling, V. (2001). Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl. Acad. Sci. U.S.A. 98, 2011-2016.
73. Wang, R., Salem, M., Yousef, I.M., Tuchweber, B., Lam, P., Childs, S.J., Helgason, C.D., Ackerley, C., Phillips, M.J., and Ling, V. (2009). Compensatory role of P-glycoproteins in knockout mice lacking the bile salt export pump. Hepatology 50, 948-956.
74. Xia, C.Q., Milton, M.N., and Gan, L.S. (2007). Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr. Drug Metab. 8, 341-363.
75. Zelcer, N., van de Wetering, K., de Waart, R., Scheffer, G.L., Marschall, H.U., Wielinga, P.R., Kuil, A., Kunne, C., Smith, A., van der Valk, et al. (2006). Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 44, 768-775.
76. Zollner, G., Marschall, H.U., Wagner, M., and Trauner, M. (2006). Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251.
77. Zollner, G., and Trauner, M. (2008). Mechanisms of cholestasis. Clin. Liver Dis. 12, 1-26.